SCHEMBL4721793

SCHEMBL4721793

N#Cc1ccc(N2CCC3(CC2)CCN([C@H]2CC[C@H](O)CC2)C3=O)nc1

nearest known ligand 0.45

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
LCAT P04180 1/20 0.45
HTR7 P34969 1/20 0.44
PANK3 Q9H999 7/20 0.44
DPP4 P27487 2/20 0.44
GPR119 Q8TDV5 1/20 0.43
HSD11B1 P28845 3/20 0.43
JAK2 O60674 3/20 0.41
JAK3 P52333 3/20 0.41
JAK1 P23458 2/20 0.41
KCNH2 Q12809 2/20 0.41
TNKS O95271 1/20 0.40
PARP1 P09874 1/20 0.40
TNKS2 Q9H2K2 1/20 0.40
DPP8 Q6V1X1 1/20 0.39
DPP9 Q86TI2 1/20 0.39
SMO Q99835 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5629301 1.00 LCAT (0.45) LCATHTR7PANK3DPP4GPR119
SCHEMBL549430 0.91 HTR7 (0.43) LCATHTR7PANK3DPP4GPR119
SCHEMBL549431 0.91 HTR7 (0.43) LCATHTR7PANK3DPP4GPR119
SCHEMBL4790365 0.83 HSD11B1 (0.47) LCATHTR7PANK3DPP4HSD11B1
SCHEMBL5630252 0.83 HSD11B1 (0.47) LCATHTR7PANK3DPP4HSD11B1
SCHEMBL4723036 0.83 HSD11B1 (0.47) LCATHTR7PANK3DPP4HSD11B1
SCHEMBL4763251 0.83 HRH3 (0.43) LCATGPR119HSD11B1PARP1
SCHEMBL5629345 0.83 LCAT (0.43) LCATPANK3HSD11B1
SCHEMBL5632593 0.83 HSD11B1 (0.47) LCATHTR7PANK3DPP4GPR119
SCHEMBL4720228 0.83 LCAT (0.43) LCATPANK3HSD11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8193207-B2 Lactam compounds and methods of using the same INCYTE CORPORATION (US) 2012-06-05 US claimed
EP-1957494-A2 LACTAM COMPOUNDS AND METHODS OF USING THE SAME Incyte Corporation (US) 2008-08-20 EP claimed
WO-2007067504-A2 LACTAM COMPOUNDS AND METHODS OF USING THE SAME INCYTE CORPORATION (US) 2007-06-14 WO claimed
US-20070129345-A1 Lactam compounds and methods of using the same INCYTE CORPORATION 2007-06-07 US claimed
US-8193207-B2 Lactam compounds and methods of using the same INCYTE CORPORATION (US) 2012-06-05 US disclosed
US-8193207-B2 Lactam compounds and methods of using the same INCYTE CORPORATION (US) 2012-06-05 US disclosed
WO-2007067504-A2 LACTAM COMPOUNDS AND METHODS OF USING THE SAME INCYTE CORPORATION (US) 2007-06-14 WO disclosed
US-20070129345-A1 Lactam compounds and methods of using the same INCYTE CORPORATION 2007-06-07 US disclosed
US-20070129345-A1 Lactam compounds and methods of using the same INCYTE CORPORATION 2007-06-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070129345-A1 Lactam compounds and methods of using the same HSD11B1, HSD17B11, HSD17B1 LCAT 268/4885HTR7 4367/4885PANK3 2352/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.